Methods to scale production of hPSC-derived endothelial cells

Reference number 10560

Sectors: Pharmaceuticals

Industries: Cardiovascular

Imperial inventors have developed a new 3D-culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells. This method allows for the large-scale production of endothelial cells, increasing their therapeutic potential, as clinical application requires millions of cells for transplantation. In addition, the inventors have found that conventional 2D-culture methods do not produce stable endothelial cell lines, with the cellular phenotype drifting to non-endothelial cell lineages within a matter of days or within one to two passages of the cells. In contrast, the 3D-culture methodology developed by the present inventors produces endothelial cells which maintain their phenotype for weeks.


The methods developed by the present inventors can produce significantly increased numbers of endothelial cells as compared to existing approaches. Advantageously, methods of the invention allow for the production of sufficient numbers of endothelial cells for downstream cell therapy applications.


  • Producing substantial quanti-ties of endothelial cells in vitro under non-human animal derived component free conditions.
  • The cells have a range of therapeutic applications (ex. Cell therapy and/or trans-plantation)
  • Scalable production of large numbers of endothelial cells in compliance with GMP standards.

Intellectual Property

This technology is subject to Priority patent application.


Dr Gabor Foldes

Advanced Research Fellow
Faculty of Medicine, National Heart & Lung Institute

Visit personal site
Professor Sian Harding

Professor of Cardiac Pharmacology
Faculty of Medicine, National Heart & Lung Institute

Visit personal site

Contact us about this technology


Dr Amritha Nair

Industry Partnerships and Commercialisation Senior Executive, Faculty of Medicine

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property; marketing of technologies primed for commercialisation and supporting commercialisation via licensing or spinouts. Amritha also supports researchers in their bids for access to translational funding. Amritha manages an extensive IP portfolio, mainly focussed on therapeutics and diagnostics. Prior roles include innovation consulting for small and medium enterprises and handling the drug development and start-up activities for a private equity backed life science development group in Houston, USA. Amritha has a PhD in Molecular and Human Genetics from Baylor College of Medicine, Houston, USA and a MSc in Human Genetics from Sri Ramachandra University, Chennai, India.

Contact Amritha

[email protected]

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.